Actinium Pharmaceuticals, Inc. - FORM 10-Q - EX-32.1 - CERTIFICATION - August 4, 2017

Attached files

file filename
EX-10.5 - AMENDED AND RESTATED AT-THE-MARKET MARKET ISSUANCE SALES AGREEMENT, DATED JULY 3 - Actinium Pharmaceuticals, Inc.f10q0617ex10v_actinium.htm
EX-10.4 - OFFER LETTER; DATED MAY 26, 2017, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. - Actinium Pharmaceuticals, Inc.f10q0617ex10iv_actinium.htm
EX-10.8 - SEPARATION AND SETTLEMENT AGREEMENT, DATED MAY 12, 2017, BY AND BETWEEN ACTINIUM - Actinium Pharmaceuticals, Inc.f10q0617ex10viii_actinium.htm
EX-32.2 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10q0617ex32ii_actiniumpharm.htm
EX-31.2 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10q0617ex31ii_actiniumpharm.htm
EX-31.1 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10q0617ex31i_actiniumpharm.htm
EX-10.9 - SEPARATION AND SETTLEMENT AGREEMENT, DATED MAY 12, 2017, BY AND BETWEEN ACTINIUM - Actinium Pharmaceuticals, Inc.f10q0617ex10ix_actinium.htm
EX-10.7 - CONSULTING AGREEMENT, DATED MAY 22, 2017, BY AND BETWEEN ACTINIUM PHARMACEUTICAL - Actinium Pharmaceuticals, Inc.f10q0617ex10vii_actinium.htm
EX-10.6 - AGREEMENT, DATED JUNE 6, 2017, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND - Actinium Pharmaceuticals, Inc.f10q0617ex10vi_actinium.htm
EX-10.3 - AMENDED AND RESTATED LICENSE AGREEMENT, DATED JUNE 8, 2017, BETWEEN ACTINIUM PHA - Actinium Pharmaceuticals, Inc.f10q0617ex10iii_actinium.htm
EX-10.1 - ASSIGNMENT AND CONSENT AGREEMENT, DATED JUNE 6, 2017, AMONG 275 MADISON AVENUE R - Actinium Pharmaceuticals, Inc.f10q0617ex10i_actinium.htm
10-Q - QUARTERLY REPORT - Actinium Pharmaceuticals, Inc.f10q0617_actiniumpharma.htm

Exhibit 32.1

  

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Actinium Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sandesh Seth, Chairman & CEO of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
2. The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: August 4, 2017 By: /s/ Sandesh Seth
    Sandesh Seth
   

Chairman & CEO

(Duly Authorized Officer and

Principal Executive Officer)

 

Actinium Pharmaceuticals, Inc. Reports